Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy

Patrick W. Reed, Andrea M. Corse, Neil C. Porter, Kevin M. Flanigan, Robert J. Bloch

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


To identify proteins expressed abnormally in facioscapulohumeral muscular dystrophy (FSHD), we extracted soluble proteins from deltoid muscle biopsies from unaffected control and FSHD patients and analyzed them using two-dimensional electrophoresis, mass spectrometry and immunoblotting. Muscles from patients with FSHD showed large increases over controls in a single soluble, 34 kDa protein (pI = 5.08) identified by mass spectrometry and immunoblotting as mu-crystallin (CRYM). Soluble fractions of biopsies of several other myopathies and muscular dystrophies showed no appreciable increases in mu-crystallin. Mu-crystallin has thyroid hormone and NADPH binding activity and so may influence differentiation and oxidative stress responses, reported to be altered in FSHD. It is also linked to retinal and inner ear defects, common in FSHD, suggesting that its up-regulation may play a specific and important role in pathogenesis of FSHD.

Original languageEnglish (US)
Pages (from-to)583-586
Number of pages4
JournalExperimental Neurology
Issue number2
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience


Dive into the research topics of 'Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy'. Together they form a unique fingerprint.

Cite this